Inari Medical Inc
NARI
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
143.4% downsideOvervalued by 143.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.68 Billion |
|---|---|
| Enterprise Value | $4.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 1.03 |
| Outstanding Shares | 58,366,364 |
Return
| Return on Equity | -18.08% |
|---|---|
| Return on Assets | -11.27% |
| Return on Invested Capital | -6.71% |
Valuation & Multiples
| P/E Ratio | -2776.74 |
|---|---|
| PEG | 407.82 |
| Price to Sales | 8.89 |
| Price to Book Ratio | 11.42 |
| Enterprise Value to Revenue | 8.14 |
| Enterprise Value to EBIT | -127.04 |
| Enterprise Value to Net Income | -60 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Inari Medical Inc
456 employeesInari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based...
Relevant Senate Committees
This committee oversees Medicare and Medicaid. Reimbursement rates and coding for venous procedures are critical to Inari’s revenue growth and market adoption.
Through its subcommittees, this committee allocates the actual cash for the FDA and HHS. Funding levels determine the speed of device reviews and the implementation of healthcare programs.
This committee oversees the FDA. Its members have direct influence over the regulatory approval processes and safety oversight for Inari's 510(k)-cleared medical devices.
Venous thromboembolism (VTE) is a condition that disproportionately affects the elderly. This committee's focus on senior healthcare quality and costs creates significant headline and policy risk for Inari.